Type 1 diabetes therapy beyond T cell targeting: Monocytes, B cells, and innate lymphocytes

Wong, F. Susan ORCID: https://orcid.org/0000-0002-2812-8845 and Wen, Li 2012. Type 1 diabetes therapy beyond T cell targeting: Monocytes, B cells, and innate lymphocytes. The Review of Diabetic Studies 9 (4) , pp. 289-304. 10.1900/RDS.2012.9.289

Full text not available from this repository.

Abstract

Recent clinical trials, investigating type 1 diabetes (T1D), have focused mainly on newly diagnosed individuals who have developed diabetes. We need to continue our efforts to understand disease processes and to rationally design interventions that will be safe and specific for disease, but at the same time not induce undesirable immunosuppression. T cells are clearly involved in the pathogenesis of T1D, and have been a major focus for both antigen-specific and non-antigen-specific therapy, but thus far no single strategy has emerged as superior. As T1D is a multifactorial disease, in which multiple cell types are involved, some of these pathogenic and regulatory cell pathways may be important to consider. In this review, we examine evidence for whether monocytes, B cells, and innate lymphocytes, including natural killer cells, may be suitable targets for intervention.

Item Type:	Article
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	The Society for Biomedical
ISSN:	1613-6071
Date of Acceptance:	21 January 2013
Last Modified:	03 Nov 2022 09:33
URI:	https://orca.cardiff.ac.uk/id/eprint/105279

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item